Results 31 to 40 of about 33,909 (215)

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

open access: yesGMS Hygiene and Infection Control, 2014
[english] Aim: The in vitro activity of colistin in combination with sulbactam, netilmicin, and vancomycin against colistin-resistant strains was investigated. Furthermore, the clonal relationship of the strains was analyzed.
Percin, Duygu   +2 more
doaj   +1 more source

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii

open access: yesFrontiers in Microbiology, 2022
Amikacin and polymyxins as monotherapies are ineffective against multidrug-resistant Acinetobacter baumannii at the clinical dose. When polymyxins, aminoglycosides, and sulbactam are co-administered, the combinations exhibit in vitro synergistic ...
Shixing Zhu   +11 more
doaj   +1 more source

Table_1_Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates.docx

open access: yes, 2022
Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii.
Grace Ra (13024683)   +9 more
core   +1 more source

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium

open access: yesPathogens, 2022
This study was designed to assess the effect of β-lactam/β-lactamase inhibitor combinations on the inhibition of biofilm formation of Salmonella Typhimurium.
Nana Nguefang Laure, Juhee Ahn
doaj   +1 more source

 -Lactamase Inhibition and In Vitro Activity of Sulbactam and Sulbactam/Cefoperazone [PDF]

open access: yesClinical Infectious Diseases, 1997
beta-Lactamase inhibitors such as sulbactam are beta-lactam compounds that have low antimicrobial activity but are able to inhibit enzymes (beta-lactamases) that destroy beta-lactam antibiotics like penicillins and cephalosporins. The main activity of beta-lactamase inhibitors is directed against plasmid-mediated transferable enzymes and various ...
openaire   +2 more sources

The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2023
Despite the presence of more than 100 different antibacterials in the therapeutic arsenal, beta-lactam antibiotics, in general, and the third-generation cephalosporins, in particular, remain the main option for the treatment of the most of infections in ...
Stetsiouk O.U.   +3 more
doaj   +1 more source

Pharmacokinetics of sulbactam in humans

open access: yesAntimicrobial Agents and Chemotherapy, 1983
Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Its half-life in humans is approximately 1 h. In a two-compartment pharmacokinetic model, the apparent volume of distribution for the central compartment is approximately 12 liters, and half of the dose is found in ...
G, Foulds   +6 more
openaire   +3 more sources

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

open access: yesAntimicrobial Resistance and Infection Control, 2019
Background We retrospectively analyzed the effect of tigecycline and cefoperazone/sulbactam therapies on the prognosis of patients with carbapenem-resistant Acinetobacter baumannii bloodstream infection (CRAB-BSI).
Tianshui Niu   +5 more
doaj   +1 more source

Alteration of adeS Contributes to Tigecycline Resistance and Collateral Sensitivity to Sulbactam in Acinetobacter baumannii

open access: yesMicrobiology Spectrum, 2023
The treatment of extensively drug-resistant (XDR) A. baumannii has emerged as a major problem. Tigecycline (TGC) and sulbactam (SUL) are both effective antibiotics against XDR A. baumannii.
Yunxing Yang   +12 more
doaj   +1 more source

Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

open access: yesAntibiotics
The treatment of Acinetobacter baumannii infections remains a challenge for physicians worldwide in the 21st century. The bacterium possesses a multitude of mechanisms to escape the human immune system. The consequences of A.
Petros Rafailidis   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy